Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Income from Continuing Operations (2022 - 2025)

Historic Income from Continuing Operations for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' Income from Continuing Operations fell 724.55% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 31.73%. This contributed to the annual value of -$8.0 million for FY2024, which is 10860.2% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Income from Continuing Operations stood at -$2.3 million, which was down 724.55% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Income from Continuing Operations ranged from a high of $4.2 million in Q3 2023 and a low of -$4.2 million during Q2 2024
  • In the last 4 years, 60 Degrees Pharmaceuticals' Income from Continuing Operations had a median value of -$2.0 million in 2023 and averaged -$1.6 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 38769.81% in 2023, then crashed by 53863.71% in 2025.
  • 60 Degrees Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$1.7 million in 2022, then fell by 22.55% to -$2.0 million in 2023, then decreased by 0.13% to -$2.0 million in 2024, then decreased by 13.09% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.9 million during Q1 2025.